Search

Your search keyword '"Doroshow, J.H."' showing total 32 results
Start Over Author "Doroshow, J.H."
32 results on '"Doroshow, J.H."'

3. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Author

Woo, X.Y., Giordano, J., Srivastava, A., Zhao, Z.-., Lloyd, M.W., de Bruijn, R., Suh, Y.-., Patidar, R., Chen, L., Scherer, S., Bailey, M.H., Yang, C.-., Cortes-Sanchez, E., Xi, Y., Wang, J., Wickramasinghe, J., Kossenkov, A.V., Rebecca, V.W., Sun, H., Mashl, R.J., Davies, S.R., Jeon, R., Frech, C., Randjelovic, J., Rosains, J., Galimi, F., Bertotti, A., Lafferty, A., O'Farrell, A.C., Modave, E., Lambrechts, D., ter Brugge, P., Marangoni, E., El Botty, R., Kim, H., Kim, J.-., Yang, H.-., Lee, C., Dean, D.A., Davis-Dusenbery, B., Evrard, Y.A., Doroshow, J.H., Welm, A.L., Welm, B.E., Lewis, M.T., Fang, B., Roth, J.A., Meric-Bernstam, F., Herlyn, M., Davies, M.A., Ding, L., Li, S., Govindan, R., Isella, C., Moscow, J.A., Trusolino, L., Byrne, A.T., Jonkers, J., Bult, C.J., Medico, E., Chuang, J.H., Robinson, P.N., Sanderson, B.J., Neuhauser, S.B., Dobrolecki, L.E., Zheng, X., Majidi, M., Zhang, R., Zhang, X., Akcakanat, A., Evans, K.W., Yap, T.A., Li, D., Yucan, E., Lanier, C.D., Saridogan, T., Kirby, B.P., M. J., H., Chen, H., Kopetz, S., Menter, D.G., Zhang, J., Westin, S.N., Kim, M.P., Dai, B., Gibbons, D.L., Tapia, C., Jensen, V.B., Boning, G., Minna, J.D., Park, H., Timmons, B.C., Girard, L., Fingerman, D., Liu, Q., Somasundaram, R., Xiao, M., Yennu-Nanda, V.G., Tetzlaff, M.T., Xu, X., Nathanson, K.L., Cao, S., Chen, F., Dipersio, J.F., Lim, K.H., C. X., M., Rodriguez, F.M., Van Tine, B.A., Wang-Gillam, A., Wendl, M.C., Wu, Y., Wyczalkowski, M.A., Yao, L., Jayasinghe, R., Aft, R.L., Fields, R.C., Luo, J., Fuh, K.C., Chin, V., Digiovanna, J., Grover, J., Koc, S., Seepo, S., Wallace, T., Pan, C.-., Chen, M.S., Carvajal-Carmona, L.G., Kirane, A.R., Cho, M., Gandara, D.R., Riess, J.W., Le, T., deVere White, R.W., Tepper, C.G., Zhang, H., Coggins, N.B., Lott, P., Estrada, A., Toal, T., Arana, A.M., Polanco-Echeverry, G., Rocha, S., A. -H., M., Mitsiades, N., Kaochar, S., O'Malley, B.W., Ellis, M.J., Hilsenbeck, S.G., Ittmann, M., Corso, S., Fiori, A., Giordano, S., van de Ven, M., Peeper, D.S., Miller, I., Bernado, C., Morancho, B., Ramirez, L., Arribas, J., Palmer, H.G., Piris-Gimenez, A., Soucek, L., Dahmani, A., Montaudon, E., Nemati, F., Dangles-Marie, V., Decaudin, D., Roman-Roman, S., Alferez, D.G., Spence, K., Clarke, R.B., Bentires-Alj, M., Chang, D.K., Biankin, A.V., Bruna, A., O'Reilly, M., Caldas, C., Casanovas, O., Gonzalez-Suarez, E., Munoz, P., Villanueva, A., Conte, N., Mason, J., Thorne, R., Meehan, T.F., Parkinson, H., Dudova, Z., Krenek, A., Stuchlik, D., Elemento, O., Inghirami, G., Golebiewska, A., Niclou, S.P., Wisman, G.B.A., de Jong, S., Kralova, P., Sedlacek, R., Claeys, E., Leucci, E., Borsani, M., Lanfrancone, L., Pelicci, P.G., Maelandsmo, G.M., Norum, J.H., Vinolo, E., Serra, V., and Leucci, Eleonora

Subjects
endocrine system diseases, Microarray, gene amplification, Whole Exome Sequencing, Mice, 0302 clinical medicine, Gene expression, Databases, Genetic, Gene duplication, Neoplasm Metastasis, Exome sequencing, Cancer, Regulation of gene expression, 0303 health sciences, Manchester Cancer Research Centre, adult, adult, animal experiment, animal model, animal tissue, breast cancer, microarray, DNA sequencing engraftment, gene amplification, tumor, xenograft, tumor-related gene, Polymorphism, Single Nucleotide/genetics, 3. Good health, Gene Expression Regulation, Neoplastic, 030220 oncology & carcinogenesis, microarray, hormones, hormone substitutes, and hormone antagonists, tumor, endocrine system, DNA sequencing engraftment, animal experiment, DNA Copy Number Variations/genetics, Biology, digestive system, DNA sequencing, Article, animal tissue, 03 medical and health sciences, breast cancer, Breast cancer, Genetics, medicine, Animals, Humans, xenograft, Gene, 030304 developmental biology, Settore MED/04 - Patologia Generale, Microarray analysis techniques, animal model, ResearchInstitutes_Networks_Beacons/mcrc, tumor-related gene, medicine.disease, Xenograft Model Antitumor Assays, Computational biology and bioinformatics, Cancer research, Human cancer
Abstract

Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting the accuracy of PDX modeling of human cancer. Here, we exhaustively analyze copy number alterations (CNAs) in 1,451 PDX and matched patient tumor (PT) samples from 509 PDX models. CNA inferences based on DNA sequencing and microarray data displayed substantially higher resolution and dynamic range than gene expression-based inferences, and they also showed strong CNA conservation from PTs through late-passage PDXs. CNA recurrence analysis of 130 colorectal and breast PT/PDX-early/PDX-late trios confirmed high-resolution CNA retention. We observed no significant enrichment of cancer-related genes in PDX-specific CNAs across models. Moreover, CNA differences between patient and PDX tumors were comparable to variations in multiregion samples within patients. Our study demonstrates the lack of systematic copy number evolution driven by the PDX mouse host., Analysis of copy number alterations in 1,451 patient-derived xenografts (PDXs) and matched patient tumor samples shows strong conservation from patient tumors through late-passage PDXs and a lack of systematic copy number evolution driven by the mouse host.

Published
2021
Full Text
View/download PDF

6. Phase I study of ganetespib and ziv-aflibercept in patients with advanced gastrointestinal carcinomas, non-squamous non-small cell lung carcinomas, urothelial carcinomas, and sarcomas

Author

Meehan, R.S., primary, Kummar, S., additional, O'Sullivan Coyne, G., additional, Zlott, J., additional, Horneffer, Y., additional, Juwara, L., additional, Streicher, H., additional, Sharon, E., additional, Harris, P., additional, Doroshow, J.H., additional, and Chen, A., additional

Published
2016
Full Text
View/download PDF

8. 233 Analytical validation and application of the MPACT assay, a next generation sequencing based targeted mutation detection assay for treatment selection

Author

Lih, C., primary, Sims, D.J., additional, Harrington, R.D., additional, Polley, E.C., additional, Zhao, Y., additional, Simon, R.M., additional, Mehaffey, M.G., additional, Forbes, T.D., additional, Walsh, W.D., additional, Datta, V., additional, Conley, B.A., additional, Chen, A.P., additional, Kummar, S., additional, Doroshow, J.H., additional, and Williams, P.M., additional

Published
2014
Full Text
View/download PDF

18. 591 Phase I Trial of Z-endoxifen with Estrogen Receptor Imaging in Adults with Refractory Hormone Receptor-positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors

Author

Kummar, S., primary, Safgren, S.L., additional, Lindenberg, M., additional, Kurdziel, K., additional, Reid, J.M., additional, Streicher, H., additional, Ames, M.M., additional, Jacobs, P., additional, Collins, J., additional, and Doroshow, J.H., additional

Published
2012
Full Text
View/download PDF

24. Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer

Author

Somlo, G., primary, Sniecinski, I., additional, Odom-Maryon, T., additional, Nowicki, B., additional, Chow, W., additional, Hamasaki, V., additional, Leong, L., additional, Margolin, K., additional, Morgan, R., additional, Raschko, J., additional, Shibata, S., additional, Tetef, M., additional, Molina, A., additional, Berenson, R.J., additional, Forman, S.J., additional, and Doroshow, J.H., additional

Published
1997
Full Text
View/download PDF

27. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer.

Author

Somlo, G., Simpson, J.F., Frankel, P., Chow, W., Leong, L., Margolin, K., Jr., R. Morgan, Raschko, J., Shibata, S., Forman, S., Kogut, N., McNamara, M., Molina, A., Somlo, E., Doroshow, J.H., and Morgan, R Jr

Subjects
BREAST cancer, P53 antioncogene, PROGESTERONE, ESTROGEN, SURVIVAL, PROGNOSIS, TUMOR classification, TREATMENT effectiveness, BREAST tumors
Abstract

We report on a predictive model of long-term outcome in 114 high-risk breast cancer patients treated with high-dose chemotherapy between 1989 and 1994. Paraffin-blocks from 90 of the 114 primaries were assessed for the presence of five risk factors: grade, mitotic index, protein expression of p53, HER2/neu, and oestrogen/progesterone receptor status; we could analyse the effect of risk factors in 84 of these 90 tumours. Seven-year relapse-free and overall survival was 58% (95% confidence interval 44-74%) and 82% (95% confidence interval 71-94%) vs 33% (95% confidence interval 21-52%) and 41% (95% confidence interval 28-60%) for patients whose primary tumours displayed > or =3 risk factors vs patients with < or =2 risk factors. For the entire group of 168 high-risk breast cancer patients, inflammatory stage IIIB disease and involved post-mastectomy margins were associated with decreased relapse-free survival and overall survival; patients treated with non-doxorubicin containing standard adjuvant therapy experienced worse overall survival (RR, 2.08; 95% confidence interval 1.04 to 4.16; P=0.04), while adjuvant tamoxifen improved overall survival (RR, 0.65; 95% confidence interval 0.41-1.01; P=0.054). Future trial designs and patient selection for studies specific for high-risk breast cancer patients should include appropriate prognostic models. Validation of such models could come from recently completed randomised, prospective trials. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

28. Total Body Irradiation and High-Dose Etoposide: A New Preparatory Regimen for Bone Marrow Transplantation in Patients With Advanced Hematologic Malignancies

Author

Blume, K.G., Forman, S.J., O’Donnell, M.R., Doroshow, J.H., Krance, R.A., Nademanee, A.P., Snyder, D.S., Schmidt, G.M., Fahey, J.L., Metter, G.E., Hill, L.R., Findley, D.O., and Sniecinski, I.J.

Abstract

In a phase I/II study, 47 patients (median age, 24 years) with hematologic malignancies (33 patients with acute leukemia not in first remission and 14 patients with other advanced malignant hematologic disorders) were treated with total body irradiation and high doses of etoposide (VP16-213) followed by bone marrow transplantation. At the time of analysis, 21 patients were alive, and 19 of them were in continued complete remission for 101 days to >40 months (median, 12 months). The actuarial disease-free survival rate of the 33 acute leukemia patients is 43% (2 SEM, 18%) and the actuarial relapse rate is 32% (2 SEM, 20%). Five of the 14 patients with the other hematologic malignancies are alive, and four of them continue to be free of disease for 8 to 27 months. Pharmacokinetic studies established a strong correlation between the administered drug doses and their plasma levels and also demonstrated complete drug clearance prior to marrow grafting. An etoposide dose of 60 mg/kg body weight was found to be the maximum tolerated dose. This new preparatory regimen was well tolerated and was not associated with specific acute or long-term regimen-related toxicities. Our data suggest that total body irradiation with high-dose etoposide presents a viable alternative to other preparatory regimens. The role of this novel combination remains to be defined by future prospective randomized trials.

Published
1987
Full Text
View/download PDF

29. Doxorubicin-induced cardiac toxicity.

Author

Doroshow, J.H.

Subjects
*HEART
Abstract

Editorial. Describes doxorubicin-induced cardiac toxicity and approaches to reducing its toxic effects. Refers to a study by Lipshultz et al. in this issue of the `Journal.'

Published
1991
Full Text
View/download PDF

30. Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad-range multidrug resistance

Author

Doroshow, J.H., Metz, M.Z., Matsumoto, L., Winters, K.A., Sakai, M., Muramatsu, M., and Kane, S.E.

Subjects
Physiological aspects, Complications and side effects, Research, Combination chemotherapy -- Physiological aspects -- Research, Gene therapy -- Research -- Physiological aspects, Transduction (Genetics) -- Physiological aspects -- Research, Transduction -- Physiological aspects -- Research, Chemotherapy, Combination -- Physiological aspects -- Research
Abstract

According to the authors' abstract of an article published in Cancer Research, 'In these experiments, we examined the ability of a retroviral vector, pHaMASV, to encode two potential chemoprotective genes [...]

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results